Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Genentech's Phase III STARGLO study shows that Columvi, in combination with chemotherapy, significantly increases survival rates for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint with a 41% reduction in the risk of death. This treatment could offer a new option for patients ineligible for transplants.
June 17, 2024 | 7:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genentech's Phase III STARGLO study demonstrates that Columvi, combined with chemotherapy, significantly improves survival rates for patients with relapsed or refractory DLBCL. This could lead to increased adoption and sales of Columvi.
The successful Phase III study results for Columvi in combination with chemotherapy indicate a significant improvement in survival rates for DLBCL patients. This could lead to higher adoption rates and increased sales, positively impacting Genentech's parent company, Roche Holding AG (RHHBY).
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100